Stochastic model of the adaptive immune response predicts disease severity and captures enhanced cross-reactivity in natural dengue infections

Hung D. Nguyen^{1,2}*, Sidhartha Chaudhury³, Adam T. Waickman⁴, Heather Friberg⁵, Jeffrey R. Currier⁵, Anders Wallqvist¹*

¹Biotechnology HPC Software Applications Institute, Telemedicine and Advanced Technology Research Center, U.S. Army Medical Research and Development Command, Fort Detrick, MD, United States;

²Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, United States;

³Center for Enabling Capabilities, Walter Reed Army Institute of Research, Silver Spring, MD, United States;

⁴Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America

⁵Viral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.

*(HDN) hnguyen@bhsai.org

*(AW) sven.a.wallqvist.civ@mail.mil

Supplemental Data

Serotype	Epitope	Sequence				
1	PrM	aaaa	aaaa	aaaa	aaaa	aaaa
1	FL	bbbb	bbbb	bbbb	bbbb	bbbb
1	DIII	сссс	сссс	cccc	сссс	сссс
1	hinge	dddd	dddd	dddd	dddd	dddd
2	PrM	aaaa	aaaa	aaaa	aaaa	aaaa
2	FL	bbbb	bbbb	bbbb	bbbb	bbb c
2	DIII	сссс	сссс	cccc	сссс	dddd
2	Hinge	dddd	dddd	dddd	ddd a	aaaa
3	PrM	aaaa	aaaa	aaaa	aaaa	aaaa
3	FL	bbbb	bbbb	bbbb	bbbb	bbb d
3	DIII	cccc	cccc	cccc	cccc	aaaa
3	hinge	dddd	dddd	dddd	ddd b	bbbb
4	PrM	aaaa	aaaa	aaaa	aaaa	aaaa
4	FL	bbbb	bbbb	bbbb	bbbb	bbb a
4	DIII	сссс	cccc	cccc	cccc	bbbb
4	hinge	dddd	dddd	dddd	ddd c	cccc

Table S1:	Sequences	and paramet	ter values for	each epitor	be of each serotype
	1	1			21

Model parameter	Symbol	Value
Simulation conditions		
Virus dose		10 ⁴ copies/ml
Virus parameters		•
Serotypes		4
Epitopes		4
Epitope PrM		
Immunogenicity	γ	0.85
Clearance	ρ	0.1
Antigenic distance		0
Epitope FL		
Immunogenicity	γ	1.50
Clearance	ρ	1.0
Antigenic distance		1
Epitope DIII		
Immunogenicity	γ	1.15
Clearance	ρ	1.0
Antigenic distance		4
Epitope hinge		
Immunogenicity	γ	1.50
Clearance	ρ	1.0
Antigenic distance		5
Virus formation rate	kv	6.2 ml/(copies x d)
Virus decay rate	gv	(8.0 h) ⁻¹
B cell parameters		
B cell enhancement factor	ε _B	10
Ab enhancement factor	ε _{Ab}	2.5
Naïve B cell formation rate*	k _N	(R h) ⁻¹
Naïve B cell stimulation	σ_{N}	$(1 d)^{-1}$
GC B cell stimulation (base)	σ_{base}	(8 h) ⁻¹
GC B cell stimulation (maximum)	σ_{max}	(15 min) ⁻¹
GC B cell replication rate	r	(8 h) ⁻¹
Mutation probability	μ	0.10
Differentiation probability	δ	0.10
Memory cell stimulation	σ_{M}	$(1 d)^{-1}$

Table S2: Parameter values for the immune system model

	Ab production	\mathbf{k}_{Ab}	1.0
	Naïve B cell decay rate	g _N	$(4.5 \text{ d})^{-1}$
	GC B cell decay rate (base)	g _B	$(4.5 \text{ d})^{-1}$
	Plasma cell decay rate	g _P	$(3 d)^{-1}$
	Ab decay rate	g _{Ab}	$(10 \text{ d})^{-1}$
Т	cell parameters		
	CD4 ⁺ T cell formation rate*	k _{T1}	R copies x (ml x d) ⁻¹
	CD4 ⁺ T cell decay rate	k _{T2}	$(4.5 \text{ d})^{-1}$
	CD8 ⁺ T cell formation rate*	k _{T3}	R copies x (ml x d) ⁻¹
	CD8 ⁺ T cell decay rate	k _{T4}	$(4.5 \text{ d})^{-1}$
	CD4 ⁺ T cell activation rate	k _{T5}	1200 ml x (copies x h) ⁻¹
	CD4 ⁺ T cell differentiation rate	k _{T6}	(15 h) ⁻¹
	Memory CD4 ⁺ T cell formation rate	k _{T7}	(15 h) ⁻¹
	Activated CD4 ⁺ T cell decay rate	k _{T8}	$(4.5 \text{ d})^{-1}$
	Memory CD4 ⁺ T cell reactivation rate	k _{T9}	2400 ml x (copies x h) ⁻¹
	CD8 ⁺ T cell activation rate	k _{T10}	8 ml x (copies x h) ⁻¹
	CD8 ⁺ -based clearance rate	k _{T11}	0.000025 ml x (copies x d)-1
	CD8 ⁺ T cell differentiation rate	k _{T12}	(180 h) ⁻¹
	Activated CD8 ⁺ T cell decay rate	k _{T13}	$(4.5 \text{ d})^{-1}$

*R: the rate constant corresponds to either naïve B cell, CD4+, or CD8+ concentration that was randomly chosen for every simulation from a non-normal distribution of a healthy population of 6-12 years old children.

Figure S1: Simulation conditions for heterotypic and homotypic infections, each set is constructed from 10,000 independent simulations





Figure S2: Affinity of germinal center B cells, memory B cells, plasma cells and antibodies from primary and secondary heterotypic infections as a function of time.

Figure S3: (A) Correlation between secondary viral peak and lymphocyte, (B) k-means clustering for disease classification, each of the four cluster is represented by a different color, the centroid of each cluster is represented as an orange dot. Each horizontal line represents a boundary value of secondary viral peak separating every two clusters.



Figure S4: Profile of recalled memory, plasma, and antibody plus fresh naïve B cells before secondary infections



Figure S5: Correlation between disease severity (secondary viral peak), secondary antibody response, recalled memory, primary antibody response and primary viral peak. All data are plotted using log scales.

